SCHEMBL1536416

SCHEMBL1536416

CCCCCCCCCCCC(=O)O[C@@H](C[C]=O)CCCCCCCCCCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.60
MAPT P10636 5/20 0.60
LMNA P02545 6/20 0.57
ALDH1A1 P00352 1/20 0.57
PRKCA P17252 1/20 0.53
PRKCE Q02156 1/20 0.53
PRKCQ Q04759 1/20 0.53
PRKCD Q05655 1/20 0.53
MEN1 O00255 3/20 0.49
GMNN O75496 3/20 0.49
KMT2A Q03164 3/20 0.49
NPSR1 Q6W5P4 3/20 0.49
TP53 P04637 3/20 0.49
TSHR P16473 3/20 0.49
CYP1A2 P05177 2/20 0.49
HSP90AA1 P07900 2/20 0.49
BLM P54132 2/20 0.49
NR1H4 Q96RI1 2/20 0.49
CYP2C9 P11712 2/20 0.49
HIF1A Q16665 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9397924 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9395408 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9397931 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9396360 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9395675 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9395566 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9395567 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9396338 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9396332 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA
SCHEMBL9395730 1.00 MAPK1 (0.60) MAPK1MAPTLMNAALDH1A1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1987000174-A2 1-O-PHOSPHONO-SACCHARIDES, METHOD FOR THE PRODUCTION AND UTILIZATION THEREOF SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) 1987-01-15 WO claimed
US-8618080-B2 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines OM PHARMA (CH) 2013-12-31 US disclosed
US-20130035479-A1 FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION OM PHARMA (CH) 2013-02-07 US disclosed
US-7915240-B2 Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines OM PHARMA (CH) 2011-03-29 US disclosed
US-20100168054-A1 Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation OM PHARMA (CH) 2010-07-01 US disclosed
EP-2106403-A2 FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION OM Pharma (CH) 2009-10-07 EP disclosed
WO-2008059035-A2 FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION OM PHARMA (CH) 2008-05-22 WO disclosed
US-7157092-B1 Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same OM PHARMA (CH) 2007-01-02 US disclosed
US-20060148678-A1 Novel acyl-dipeptide-like compounds, a method for preparing the same and pharmaceutical compositions containing such products OM PHARMA 2006-07-06 US disclosed
EP-0316934-B1 MURAMYL PEPTIDE DERIVATIVES AND USE THEREOF Hasegawa, Akira (JP) 1993-08-18 EP disclosed
EP-0330715-B1 DISACCHARIDE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1993-06-16 EP disclosed
US-4895835-A IMMUNOMODULATORS NISSHIN OIL MILLS, LTD. (JP) 1990-01-23 US disclosed
EP-0316934-A2 Muramyl peptide derivatives and use thereof Hasegawa, Akira (JP) 1989-05-24 EP disclosed
WO-1987000174-A3 1-O-PHOSPHONO-SACCHARIDES, METHOD FOR THE PRODUCTION AND UTILIZATION THEREOF SANDOZ AG (AT) 1987-10-22 WO disclosed
WO-1987000174-A2 1-O-PHOSPHONO-SACCHARIDES, METHOD FOR THE PRODUCTION AND UTILIZATION THEREOF SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) 1987-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148678-A1 Novel acyl-dipeptide-like compounds, a method for preparing the same and pharmaceutical compositions containing such products PTMS, DNPEP, QPCT MAPK1 3826/4885MAPT 3176/4885LMNA 3556/4885
US-20130035479-A1 FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION FUT6, FUT5, B3GNT2 MAPK1 321/4885MAPT 4267/4885LMNA 3039/4885
US-20100168054-A1 Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation FUT6, FUT5, B3GNT2 MAPK1 321/4885MAPT 4267/4885LMNA 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.